Consider Xadago a Me-Too MAO-B Inhibitor for Parkinson's Disease

July 2017

Xadago (ZAH-dah-goh) will be a new add-on for Parkinson's disease.

Think of Xadago (safinamide) as similar to selegiline (Eldepryl, etc) or rasagiline (Azilect, etc).

These selective MAO-B inhibitors prevent dopamine breakdown to reduce "off-time"...when carbidopa/levodopa wears off and symptoms worsen.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Diabetes Watch for Amputation Warnings With Diabetes Med Invokana
Statins Re-Evaluate Statin Use in Older Patients WithOUT CV Disease
Corticosteroids Know the Risks and Benefits of Short-Course Steroids
Inhalers Be Prepared to Switch Patients to New Fluticasone/Salmeterol Inhalers
Heart Failure Don't Jump to Newer Drugs for Systolic Heart Failure
Osteoporosis Stick With Bisphosphonates First-Line for Most Postmenopausal Women
Transdermal Patches Help Avoid Common Errors With Transdermal Patches
Anticoagulants Double-Check Dosing of Direct Oral Anticoagulants (DOACs) in Certain Patients
UTIs Compare Options for Preventing Recurrent UTIs
Parkinson's Disease Consider Xadago a Me-Too MAO-B Inhibitor for Parkinson's Disease
Musculoskeletal Sort Through Options for Treating Nocturnal Leg Cramps